The plasma fractionation market is valued at 19.93 Billion in 2017 and is expected to grow at a CAGR of 6.8% during the forecast period (2018 to 2023), to reach to USD 29.50 Billion by 2023. Base year considered for the report is 2017.
Rising new indications for plasma products, rising adoption of SCIg, increasing installation of fractionators in plasma collection centers, and the high growth of the plasma products market in China are the major trends in this market.
This report analyzes the plasma fractionation market by product, application, end user, and region. By product, the market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. Immunoglobulins are further segmented into intravenous, subcutaneous, and other immunoglobulins. The intravenous immunoglobulins accounted for the largest share of the immunoglobulin market in 2017. This can be attributed to the ease of administration and wide indications of intravenous immunoglobulins for various neurological diseases including multiple sclerosis, neuropathic pain, chronic fatigue syndrome, and post-polio syndrome.
Request FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284
Geographically, the global plasma fractionation market is segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East and Africa. In 2017, North America accounted for the largest share of this market. North America’s prominence in this market is mainly attributed to the increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for diagnosed patients. In addition, the rising number of registered hemophilic patients is also propelling the growth of this market.
CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) dominated the global plasma fractionation market. Some of the other players competing in this market are LFB (France), Kedrion (Italy), Biotest (Germany), Sanquin (Netherlands), China Biologic Product, Bio Product Laboratory (UK), Japan Blood Products Organization, Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Beijing Tiantan Biological Products (China), and Bharat Serums and Vaccines (India).
